Nurix Therapeutics, Inc.(NRIX)Earnings, Financials & Key RatiosNurix Therapeutics, Inc. (NRIX) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's rapid cash depletion, highlighted by a $175.8 million reduction in cash reserves in 2026Q1, suggests significant dilution risk for shareholders in the near term.
Nurix Therapeutics, Inc. (NRIX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Nurix Therapeutics, Inc. (NRIX) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 8, 2026 | $0.79vs $0.76-3.9% | $6Mvs $14M-56.1% |
| Q1 2026 | Jan 28, 2026 | $0.82vs $0.84+2.4% | $14Mvs $13M+1.3% |
| Q4 2025 | Oct 9, 2025 | $1.03vs $0.84-22.6% | $8Mvs $12M-35.6% |
| Q3 2025 | Jul 9, 2025 | $0.52vs $0.71+26.8% | $44Mvs $18M+151.6% |
Recent stock market news and headlines for Nurix Therapeutics, Inc. (NRIX)
Nurix Therapeutics (NRIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The mean of analysts' price targets for Nurix Therapeutics (NRIX) points to a 29.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
NRIX rallies on its collaboration with Roche for bexobrutideg, featuring a $700 million upfront payment and potential milestone payouts of up to $2.3 billion.
Nurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Key metrics vs top competitors for Nurix Therapeutics, Inc. (NRIX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $24.40 | $2.11B | -8.00 | 53.95% | -314.9% | -49.63% | — | |
| $8.59 | $554.24M | -6.71 | -0.3% | -247.54% | -44.39% | — | |
| $119.24 | $9.74B | -32.31 | -16.72% | -612.17% | -25.02% | — | |
| $323.95 | $9.36B | -24.03 | -100% | — | -43.02% | — | |
| $37.92 | $3.9B | -46.81 | 120.01% | -49.17% | -5.89% | — | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — |
Nurix Therapeutics, Inc. (NRIX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Nurix Therapeutics, Inc. (NRIX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jun 11, 2026·SEC
Jun 8, 2026·SEC
May 15, 2026·SEC
Get notified when NRIX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Nurix Therapeutics, Inc. (NRIX) stock FAQ — growth, dividends, profitability & financials explained
Nurix Therapeutics, Inc. (NRIX) reported $71.8M in revenue for fiscal year 2025. This represents a 92% increase from $37.4M in 2018.
Nurix Therapeutics, Inc. (NRIX) grew revenue by 54.0% over the past year. This is strong growth.
Nurix Therapeutics, Inc. (NRIX) reported a net loss of $295.3M for fiscal year 2025.
Nurix Therapeutics, Inc. (NRIX) has a return on equity (ROE) of -49.6%. Negative ROE indicates the company is unprofitable.
Nurix Therapeutics, Inc. (NRIX) had negative free cash flow of $271.9M in fiscal year 2025, likely due to heavy capital investments.
